查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014484

经肠营养市场：按产品类型、剂型、给药途径、分销管道和年龄组分類的全球市场预测 – 2026-2032 年

Enteral Nutrition Market by Product Type, Form, Route Of Administration, Distribution Channel, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，经肠营养市场价值将达到 71 亿美元，到 2026 年将成长至 77.4 亿美元，到 2032 年将达到 139.9 亿美元，年复合成长率为 10.17%。

主要市场统计数据
基准年 2025 71亿美元
预计年份：2026年 77.4亿美元
预测年份 2032 139.9亿美元
复合年增长率 (%) 10.17%

本文旨在透过策略性介绍，解释为何经肠营养现在需要整合临床、营运和商业策略，以促进更好的患者疗效和系统韧性。

经肠营养在急性和长期临床护理中发挥核心作用，它将医疗需求与以患者为中心的营养支持相结合。临床医生和采购经理越来越认识到，肠内治疗不仅仅是一种消耗品，而是护理路径中不可或缺的一部分。製剂的选择、给药途径和取得模式对治疗结果和医疗资源的利用有显着的影响。因此，明智的决策需要一个综合的观点，将临床证据、供应的连续性和商业性趋势纳入考量。

临床创新、数位化照护模式和供应链现代化如何同时重塑经肠营养的产品设计、处方行为和分销策略。

经肠营养领域正经历一场变革，其驱动力包括临床创新、数位整合以及不断变化的医疗环境。製剂科学已超越了传统的热量补充，将免疫调节、疾病特异性营养混合物和基于微生物组的营养强化等治疗方法纳入其中。临床医生也正根据患者的个别表型和合併症来优化处方实践。同时，远端医疗和远端患者监护的普及使得更严格的后续观察、用药依从性追踪和及时的产品调整成为可能，进而影响着产品的设计和包装要求。

评估 2025 年关税措施对经肠营养的原料采购、供应链韧性和筹资策略的累积影响。

2025年即将实施的进口医疗和营养品关税措施，使得经肠营养链各环节的成本结构和供应链风险备受关注。依赖进口原料、特殊配料和成品组件的生产商面临着不断上涨的进口成本，这促使他们重新评估筹资策略，并在某些情况下分阶段调整产品配方以减轻关税的影响。为此，采购部门正在加强对总拥有成本（TCO）的审查，并探索合约保障措施，以更公平地分摊供应链中的关税风险。

详细的細項分析解释了产品类型、配方、给药途径、分销管道和年龄层如何影响临床选择和商业性优先顺序。

市场区隔分析揭示了每种产品类型、剂型、给药途径、分销管道和年龄层所面临的不同机会和挑战。就产品类型而言，市场包括混合营养食品、特殊营养食品和标准营养食品。特殊营养食品又可细分为疾病特异性疗法、膳食纤维强化配方、免疫调节产品和益生菌混合物。疾病特异性产品可针对糖尿病、肝臟、肺部和肾臟疾病等适应症进行客製化。另一方面，标准营养食品则分为模组化、寡聚物或聚合物。这些区分至关重要，因为临床实践中的处方行为越来越强调製剂的特异性及其与支持标靶营养介入的证据的一致性。

概述美洲、欧洲、中东、非洲和亚太地区的竞争格局和法规，这些因素决定了製造业的优先事项和打入市场策略。

区域趋势显示，美洲、欧洲、中东和非洲以及亚太地区在医疗保健基础设施、报销模式和製造地方面存在显着差异。美洲的特点是医院系统整合和居家照护市场成熟，与支付方的谈判和价值验证对于产品渗透至关重要。相较之下，欧洲、中东和非洲地区的法规环境和采购方式各不相同，采用集中竞标系统、各国特定的临床指南以及不断发展的报销途径。亚太地区的成长模式则呈现多样性，既包括特定经济区强大的国内製造业能力，也包括都市区快速扩张的家庭营养服务。

主要企业如何透过在治疗领域进行专业化、供应链优势、建立循证伙伴关係以及提供综合服务来脱颖而出并确保在临床环境中得到应用。

经肠营养领域的主要企业正透过整合配方创新、临床证据的累积以及对供应链的投资来脱颖而出。一些企业优先考虑治疗领域专业化，开发特异性疾病的配方，并辅以针对性的临床试验以及与医疗系统进行的真实世界数据（REW）合作。另一些企业则专注于卓越运营，例如优化生产规模、投资品管体係以及拓展低温运输和包装能力，以确保产品完整性。策略伙伴关係、契约製造协议以及与居家照护机构和数位健康平台的合作，正逐渐成为加速产品推广和提升服务品质的有效途径。

为加强经肠营养领域的采购韧性、证据生成、数位化护理整合和商业性伙伴关係，提出切实可行的策略和营运建议。

产业领导者应采取一系列切实可行的措施，以平衡临床价值、营运韧性和商业性可行性。首先，应实现筹资策略多元化，减少对单一原料来源的依赖，同时认证替代供应商，以维持稳定的供应，并降低关税造成的成本波动风险。其次，应优先建构兼顾产品系列和高利润率特种产品的产品组合，这些特种产品需有临床证据和真实世界数据支持，以证明其对患者的益处和经济价值。

透过结合第二手资料、专家访谈和检验的严谨多方面调查方法，我们得出对经肠营养决策有用的实践者层面的见解。

本调查方法结合了系统性的二手资料研究、有针对性的一手访谈以及严谨的检验，以确保研究结果的可靠性和对相关人员的相关性。二手资料包括同行评审的临床文献、监管指导文件、製造商技术文件和公共采购记录。这些资讯来源揭示了产品选择和市场趋势背后的临床和政策背景。一手访谈包括对临床医生、註册营养师、医院药剂师、供应链经理和居家照护提供者进行结构化访谈，以了解他们的实践模式、采购重点和营运挑战。

对于经肠营养领域的相关人员，整合是将临床特异性、供应弹性和以结果为导向的商业化联繫起来的明确策略挑战的结论。

总之，经肠营养系统正从商品化的供应模式转向以结果主导的市场模式转变，在这个市场中，配方特异性、供应链韧性和整合式服务交付决定着竞争优势。相关人员必须平衡临床需求与营运实际情况，透过投资实证实践、实现供应链多元化以及采用能够提高用药依从性和改善真实世界临床结果的数位化工具来实现这一目标。临床团队、采购、法规事务和销售部门的领导者之间的跨职能协作对于实现这些转变以及将获得的洞见转化为可执行的方案至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章经肠营养市场：依产品类型划分

  • 混合食物
  • 专用配方
    • 疾病特异性类型
      • 糖尿病
      • 对于肝臟
      • 呼吸系统
      • 肾
    • 富含纤维
    • 免疫调节
    • 含有益生菌
  • 标准配方
    • 模组化的
    • 寡聚物
    • 聚合物

第九章经肠营养市场：依形式划分

  • 液体
  • 粉末

第十章经肠营养市场：依给药途径划分

  • 口服营养
  • 肠内营养

第十一章经肠营养市场：依分销管道划分

  • 医院药房
  • 线上管道
  • 零售药房

第十二章经肠营养市场：依年龄组别划分

  • 成人版
  • 儿童

第十三章经肠营养市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章经肠营养市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章经肠营养市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国经肠营养市场

第十七章：中国经肠营养市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Danone SA
  • DSM Nutritional Products AG
  • Fresenius Kabi AG
  • Global Health Products, Inc.
  • Hormel Foods Corporation
  • Kate Farms Inc.
  • Mead Johnson & Company, LLC
  • Medtrition Inc.
  • Meiji Holdings Co., Ltd.
  • Nestle SA
  • Nutricia Advanced Medical Nutrition
  • Nutritional Medicinals, LLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Perrigo Company plc
  • Real Food Blends LLC
  • Reckitt Benckiser Group PLC
  • Victus Inc.
Product Code: MRR-4348D129FAAF

The Enteral Nutrition Market was valued at USD 7.10 billion in 2025 and is projected to grow to USD 7.74 billion in 2026, with a CAGR of 10.17%, reaching USD 13.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.10 billion
Estimated Year [2026] USD 7.74 billion
Forecast Year [2032] USD 13.99 billion
CAGR (%) 10.17%

A strategic introduction explaining why enteral nutrition now demands integrated clinical, operational, and commercial strategies to drive better patient outcomes and system resilience

Enteral nutrition occupies a central role in acute and long-term clinical care, bridging the gap between medical necessity and patient-centered nutritional support. Clinicians and procurement leaders increasingly view enteral therapies not merely as consumables but as integral elements of care pathways where formulation choice, route of administration, and access models materially affect outcomes and healthcare resource utilization. As a result, informed decision-making demands an integrated view of clinical evidence, supply continuity, and commercial dynamics.

This executive summary sets the stage for a strategic assessment of the enteral nutrition environment by synthesizing drivers that influence product selection, adoption, and procurement. It also highlights the interplay between technological innovation, regulatory oversight, and evolving care settings such as in-hospital critical care, outpatient management, and home enteral nutrition. By situating clinical needs within operational realities, the introduction clarifies why stakeholders should prioritize resilience, patient-centered design, and evidence-based differentiation as core pillars of strategy going forward.

How clinical innovation, digital care models, and supply chain modernization are simultaneously reshaping product design, prescribing behavior, and distribution strategies in enteral nutrition

The enteral nutrition landscape is undergoing transformative shifts driven by clinical innovation, digital integration, and changing care settings. Formulation science has advanced beyond standard caloric replacement to include therapeutic modalities such as immune modulation, disease-specific nutrient blends, and microbiome-informed enrichment, prompting clinicians to refine prescribing practices based on individual patient phenotypes and comorbidities. Simultaneously, the proliferation of telehealth and remote patient monitoring enables more rigorous follow-up, adherence tracking, and timely product adjustments, which in turn influences product design and packaging requirements.

Operationally, increased pressure on hospital budgets and the continued expansion of home-based care have altered distribution priorities; payers and providers place higher value on demonstrable clinical outcomes and cost-of-care reductions than on unit price alone. This shift encourages manufacturers to pursue evidence-generation partnerships with health systems and to offer services that support training, patient education, and adherence. Moreover, supply chain modernization-through nearshoring, strategic inventory management, and digital traceability-has become a competitive differentiator as organizations seek to mitigate risk and ensure continuity of care.

Assessing the cumulative effects of 2025 tariff measures on raw material sourcing, supply chain resilience, and procurement strategies for enteral nutrition stakeholders

The introduction of tariffs affecting imported medical and nutritional inputs in 2025 has amplified attention on cost structures and supply chain exposure across the enteral nutrition value chain. Manufacturers that rely on imported raw materials, specialized ingredients, and finished-goods components have faced higher landed costs, prompting reassessment of sourcing strategies and, in some cases, incremental product reformulation to reduce tariff sensitivity. Procurement teams have responded by increasing scrutiny of total cost of ownership and by seeking contractual protections that allocate tariff risk more equitably along the supply chain.

Beyond direct cost implications, tariffs have accelerated conversations about local manufacturing capacity and strategic inventory positioning. For healthcare providers, the immediate consequence has been heightened emphasis on supplier diversification and contingency planning to avoid interruptions in clinically necessary supplies. For manufacturers, tariffs have created incentives to evaluate regional manufacturing hubs, qualify alternate suppliers, and invest in raw material substitution where clinically acceptable. In the medium term, these dynamics may also influence product labeling, packaging strategies, and the economics of value-added services tied to clinical outcomes and adherence.

A granular segmentation analysis explaining how product type, formulation, administration route, distribution channel, and age cohorts drive clinical choice and commercial prioritization

Segmentation analysis reveals differentiated opportunities and challenges across product types, forms, routes of administration, distribution channels, and age cohorts. In terms of product type, the market encompasses blenderized diets, specialized formulas, and standard formulas; within specialized formulas, further differentiation exists for disease-specific therapies, fiber-enriched compositions, immune-modulating products, and probiotic-supplemented blends, while disease-specific offerings can be tailored for diabetic, hepatic, pulmonary, and renal indications; standard formulas in turn can be modular, oligomeric, or polymeric. These distinctions matter because clinical prescribing behavior increasingly aligns with the specificity of the formulation and the evidence supporting targeted nutrient interventions.

Form factors such as liquid and powder influence logistics, storage, and patient adherence, with powders offering advantages in shelf life and shipping efficiency and liquids providing convenience for clinical settings. Route of administration splits between oral nutrition and tube feeding, each with unique clinical protocols, packaging needs, and caregiver education requirements. Distribution channels include hospital pharmacies, online channels, and retail pharmacies, and each channel requires tailored commercial and regulatory approaches to optimize availability and reimbursement. Age-based segmentation separates adult and pediatric cohorts, underscoring the need for age-appropriate nutrient profiles, dosing strategies, and packaging formats that support caregiver administration and regulatory compliance.

Regional competitive and regulatory contours across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine manufacturing priorities and market access approaches

Regional dynamics exhibit meaningful variation driven by healthcare infrastructure, reimbursement models, and manufacturing footprints across the Americas, Europe Middle East & Africa, and Asia-Pacific. The Americas typically feature consolidated hospital systems and a mature home care market where payer negotiations and value demonstration are pivotal to product uptake. In contrast, Europe Middle East & Africa presents a mosaic of regulatory environments and procurement approaches, where centralized tendering coexists with country-specific clinical guidelines and evolving reimbursement pathways. Asia-Pacific is characterized by heterogenous growth patterns, ranging from robust domestic manufacturing capacity in certain economies to rapidly expanding home nutrition services in urban centers.

These geographic differences influence strategic choices by manufacturers and distributors, including where to establish regional manufacturing or fill-and-finish operations, how to prioritize clinical evidence generation, and which distribution partnerships best enable market access. Furthermore, regulatory timelines and tariff regimes vary across these regions, affecting speed-to-market and the relative attractiveness of domestic versus export-oriented production strategies. Understanding these regional contours is therefore essential for aligning commercial investments with local payer expectations and clinical practice.

How top players differentiate through therapeutic specialization, supply chain strength, evidence partnerships, and integrated service offerings to secure clinical adoption

Leading organizations in the enteral nutrition space are differentiating through a combination of formulation innovation, clinical evidence generation, and supply chain investments. Some firms prioritize therapeutic specialization, developing disease-specific formulas supported by targeted clinical studies and real-world evidence collaborations with health systems. Others focus on operational excellence-optimizing manufacturing scale, investing in quality systems, and extending cold chain and packaging competencies to ensure product integrity. Strategic partnerships, contract manufacturing arrangements, and alliances with homecare providers and digital health platforms have emerged as effective ways to accelerate adoption and enhance service offerings.

Across the competitive landscape, successful players balance portfolio breadth with depth: they maintain standardized options for broad adoption while selectively investing in premium or specialty products that command differentiated clinical value. Additionally, companies that integrate educational services for clinicians and caregivers, leverage digital adherence tools, and demonstrate cost-of-care benefits in payer-facing materials tend to secure more favorable contracting outcomes. Finally, agility in regulatory compliance and the ability to respond to regional tariff or supply disruptions have become important determinants of sustained commercial performance.

Actionable strategic and operational recommendations to strengthen sourcing resilience, evidence generation, digital care integration, and commercial partnerships in enteral nutrition

Industry leaders should pursue a set of practical measures that align clinical value with operational resilience and commercial viability. First, diversify sourcing strategies to reduce exposure to single-origin raw materials and to mitigate tariff-driven cost volatility, while simultaneously qualifying alternate suppliers to maintain consistent supply. Second, prioritize formulation portfolios that balance broad-use standard formulas with higher-margin specialized products supported by clinical evidence and real-world data that demonstrate patient benefit and economic value.

Third, invest in digital tools and service models that improve adherence, support remote monitoring, and provide measurable outcomes data for payers and health systems. Fourth, strengthen partnerships with hospital pharmacies, homecare providers, and online distributors to create seamless patient journeys from prescription to home delivery. Fifth, evaluate regional manufacturing or fill-and-finish options where tariffs and logistics materially affect total landed cost, and ensure regulatory pathways are proactively managed. By taking these actions, leaders can reduce supply risk, increase clinical adoption, and position their offerings as integral components of value-based care initiatives.

A rigorous multi-method research approach combining secondary evidence, expert interviews, and triangulation to produce practitioner-relevant insights for enteral nutrition decisions

The research methodology combines systematic secondary research, targeted primary interviews, and rigorous triangulation to ensure the findings are robust and relevant to stakeholders. Secondary inputs include peer-reviewed clinical literature, regulatory guidance documents, manufacturer technical dossiers, and public procurement records; these sources frame the clinical and policy context that underpins product selection and market behavior. Primary research comprises structured interviews with clinicians, dietitians, hospital pharmacists, supply chain managers, and homecare providers to capture practice patterns, procurement priorities, and operational pain points.

Data were synthesized using triangulation methods to reconcile differences between published evidence and practitioner insights, and scenario analyses were employed to assess the operational implications of supply shocks, tariff shifts, and changes in care delivery models. Quality assurance protocols included cross-validation of key findings with subject-matter experts and a final editorial review to ensure clarity and applicability. Together, these methods produce a balanced, practitioner-focused evidence base suitable for informing procurement, clinical pathway design, and commercial strategy.

Concluding synthesis that ties clinical specificity, supply resilience, and outcome-focused commercialization into a clear strategic imperative for stakeholders in enteral nutrition

In conclusion, the enteral nutrition ecosystem is maturing from a commoditized supply model toward an outcome-driven market where formulation specificity, supply chain resilience, and integrated service offerings determine competitive advantage. Stakeholders must reconcile clinical imperatives with operational realities by investing in evidence generation, diversifying supply chains, and adopting digital tools that enhance adherence and real-world outcomes. These shifts require cross-functional collaboration among clinical teams, procurement, regulatory affairs, and commercial leaders to translate insights into actionable programs.

As organizations navigate tariff pressures, regional regulatory variation, and evolving care settings, the imperative is clear: align product development and commercial strategies with measurable clinical and economic value. Those who do will be better positioned to secure preferred contracting, support improved patient outcomes, and sustain growth in an increasingly complex and opportunity-rich environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enteral Nutrition Market, by Product Type

  • 8.1. Blenderized Diet
  • 8.2. Specialized Formulas
    • 8.2.1. Disease Specific
      • 8.2.1.1. Diabetic
      • 8.2.1.2. Hepatic
      • 8.2.1.3. Pulmonary
      • 8.2.1.4. Renal
    • 8.2.2. Fiber Enriched
    • 8.2.3. Immune Modulating
    • 8.2.4. Probiotic Supplemented
  • 8.3. Standard Formulas
    • 8.3.1. Modular
    • 8.3.2. Oligomeric
    • 8.3.3. Polymeric

9. Enteral Nutrition Market, by Form

  • 9.1. Liquid
  • 9.2. Powder

10. Enteral Nutrition Market, by Route Of Administration

  • 10.1. Oral Nutrition
  • 10.2. Tube Feeding

11. Enteral Nutrition Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Channel
  • 11.3. Retail Pharmacies

12. Enteral Nutrition Market, by Age Group

  • 12.1. Adult
  • 12.2. Pediatric

13. Enteral Nutrition Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Enteral Nutrition Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Enteral Nutrition Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Enteral Nutrition Market

17. China Enteral Nutrition Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun Melsungen AG
  • 18.7. Baxter International Inc.
  • 18.8. Danone S.A.
  • 18.9. DSM Nutritional Products AG
  • 18.10. Fresenius Kabi AG
  • 18.11. Global Health Products, Inc.
  • 18.12. Hormel Foods Corporation
  • 18.13. Kate Farms Inc.
  • 18.14. Mead Johnson & Company, LLC
  • 18.15. Medtrition Inc.
  • 18.16. Meiji Holdings Co., Ltd.
  • 18.17. Nestle S.A.
  • 18.18. Nutricia Advanced Medical Nutrition
  • 18.19. Nutritional Medicinals, LLC
  • 18.20. Otsuka Pharmaceutical Co., Ltd.
  • 18.21. Perrigo Company plc
  • 18.22. Real Food Blends LLC
  • 18.23. Reckitt Benckiser Group PLC
  • 18.24. Victus Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENTERAL NUTRITION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENTERAL NUTRITION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY BLENDERIZED DIET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY BLENDERIZED DIET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY BLENDERIZED DIET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DIABETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DIABETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DIABETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HEPATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HEPATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HEPATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FIBER ENRICHED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FIBER ENRICHED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FIBER ENRICHED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY IMMUNE MODULATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY IMMUNE MODULATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY IMMUNE MODULATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PROBIOTIC SUPPLEMENTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PROBIOTIC SUPPLEMENTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PROBIOTIC SUPPLEMENTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY MODULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY MODULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY MODULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY OLIGOMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY OLIGOMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY OLIGOMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POLYMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POLYMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POLYMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ORAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ORAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ORAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY TUBE FEEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY TUBE FEEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY TUBE FEEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)